South Africa launches COVID-19 vaccination program with Johnson & Johnson shot

Published: Updated:

South Africa launched its COVID-19 vaccination drive on Wednesday, battling to tame a more infectious variant of the coronavirus with a roll-out of the Johnson & Johnson shot for the first time outside a clinical trial.

Authorities in South Africa have recorded almost half of the COVID-19 deaths in all of Africa and over a third of confirmed infections on the continent, but has lagged wealthier Western nations in launching mass immunization programs.

The government plans to vaccinate 40 million people, or two-thirds of the population in Africa’s most industrialized economy, to achieve some level of herd immunity.

For more coronavirus news, visit our dedicated page.

“The Johnson & Johnson vaccine has been shown in extensive trials to be safe and efficacious and will protect our health care workers from illness and death from COVID-19,” President Cyril Ramaphosa said in a statement.

The J&J shot is being deployed for the first time outside of a major clinical trial as part of a research study targeting up to 500,000 healthcare workers. J&J has been submitting data to South African medicines regulator SAHPRA to secure registration for a larger-scale roll-out.

For all the latest headlines follow our Google News channel online or via the app.

Nurse Zoliswa Gidi-Dyosi was the first to be vaccinated at Khayelitsha District Hospital in Cape Town, followed by a doctor, a member of the hospital’s housekeeping staff and an administrative clerk, the government said.

Ramaphosa and Health Minister Zweli Mkhize were vaccinated soon afterward.

South Africa is one of the first nations on the continent, along with Rwanda, Morocco and Egypt, to vaccinate against COVID-19.

A vial of the AstraZeneca/Oxford COVID-19 vaccine is pictured at the Lochee Health Center in Dundee. (File photo: AFP)
A vial of the AstraZeneca/Oxford COVID-19 vaccine is pictured at the Lochee Health Center in Dundee. (File photo: AFP)

Astrazeneca shot shelved

Ramaphosa’s government has been under pressure to get the first shots in arms quickly after pausing the roll-out of AstraZeneca’s vaccine earlier this month.

The decision to suspend use of the AstraZeneca jab came after preliminary trial data indicated that it offered minimal protection against mild to moderate illness from the 501Y.V2 variant dominant in the country. The suspension has deepened skepticism among some South Africans about COVID-19 vaccines.

Ramaphosa said earlier on Wednesday 80,000 J&J doses were being prepared for distribution across the country and that he would get inoculated on the first day of the program to demonstrate his government’s confidence in the J&J vaccine.

He said most vaccination centers would be ready to begin immunizations on Wednesday.

The 501Y.V2 virus variant, first identified by South African genomics scientists late last year, has alarmed health experts for its ability to potentially evade the immune response generated by prior exposure to the coronavirus or vaccines.

The government has said it could sell or swap its AstraZeneca doses for shots of another vaccine.

AstraZeneca says it believes its vaccine protects against severe COVID-19 and that it has started adapting it against the 501Y.V2 variant.

Read more:

Coronavirus: Africa exceeds three million COVID-19 cases, 30 pct in South Africa

Coronavirus: Higher COVID risk for black patients than white says South Africa report

What we know about the South African coronavirus variant

Top Content Trending